Fulgent Genetics, Inc. (NASDAQ: FLGT) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $676M. The Maz Rating grades it against the other companies in its sector.
Fulgent Genetics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $24.21, Fulgent Genetics, Inc. trades at 2.0x sales and 0.7x book value. Over the last twelve months it generated about $332M of revenue and a net loss of $87M. It runs a gross margin of 33.8%, an operating margin of -38.5% and a net margin of -27.5%. It shows return on equity of -8.8%, return on invested capital of -11.7% and a free cash flow yield of -0.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 5.34. Over the past 52 weeks the share price ranged from $13.46 to $31.04, with a beta of 1.00.
Fulgent Genetics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Fulgent Genetics, Inc. (FLGT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.33% / 30% · (Cash+Inv) / Mkt Cap (36m) 110.7% / 30% · Interest income / Revenue 9.46% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.33% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 49.7% / 33% · Receivables / Mkt Cap (36m) 11.7% / 49% · Interest income / Revenue 9.46% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.33% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 49.7% / 33.33% · Receivables / Mkt Cap (24m) 11.7% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.18% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 25.6% / 33.33% · Receivables / Avg Assets (4Q) 6.77% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
| FTSE | Debt / Total Assets 0.18% / 33.33% · (Cash+ST Inv) / Total Assets 27.1% / 33.33% · (Cash+Recv) / Total Assets 33.5% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
No. As of September 2026, Fulgent Genetics, Inc. (FLGT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Fulgent Genetics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 9.46% of each dividend: Fulgent Genetics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.